Neurocrine Biosciences | NBIX - Créanciers Commerciaux





Créanciers Commerciaux Changement Date
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
ALKERMES USD 102.36M 5.59M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amgen USD 19.52B 1.37B 2026-03
Biogen USD 358.5M 73.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Cytokinetics USD 24.71M 80.91M 2026-03
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Exelixis USD 24.15M 5.47M 2026-03
Gilead Sciences USD 645M 70M 2026-03
Halozyme Therapeutics USD 14.1M 6.8M 2026-03
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pfizer USD 4.51B 734M 2026-03
Prothena USD 4.3M 1.58M 2026-03
Regeneron Pharmaceuticals USD 1.03B 4.81B 2026-03
Repligen USD 34.66M 4.65M 2026-03
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
Teva Pharmaceutical Industries USD 2.6B 65M 2026-03
Ultragenyx Pharmaceutical USD 42M 11M 2026-03
Vertex Pharmaceuticals USD 3.47B 40.6M 2026-03
Xoma USD 2.65M 1.52M 2025-09